{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T07:12:16Z","timestamp":1790233936575,"version":"4.1.0"},"reference-count":29,"publisher":"Japanese Pharmacological Society","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Pharmacol Sci"],"published-print":{"date-parts":[[2011]]},"DOI":"10.1254\/jphs.10285fp","type":"journal-article","created":{"date-parts":[[2011,2,24]],"date-time":"2011-02-24T00:20:15Z","timestamp":1298506815000},"page":"346-353","source":"Crossref","is-referenced-by-count":33,"title":["SM-368229, a Novel Selective and Potent Non-steroidal Mineralocorticoid Receptor Antagonist With Strong Urinary Na+ Excretion Activity"],"prefix":"10.1254","volume":"115","author":[{"given":"Tetsuro","family":"Nariai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuya","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaya","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiji","family":"Katayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiji","family":"Hori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuki","family":"Matsui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"332","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Struthers A, Krum H, Williams GH. A comparison of the aldosterone-blocking agents eplerenone and spironolactone. Clin Cardiol. 2008;31:153–158.","DOI":"10.1002\/clc.20324"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Muldowney JA 3rd, Schoenhard JA, Benge CD. The clinical pharmacology of eplerenone. Expert Opin Drug Metab Toxicol. 2009;5:425–432.","DOI":"10.1517\/17425250902837973"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Maron BA, Leopold JA. Aldosterone receptor antagonists: effective but often forgotten. Circulation. 2010;121:934–939.","DOI":"10.1161\/CIRCULATIONAHA.109.895235"},{"key":"4","doi-asserted-by":"publisher","DOI":"10.1254\/jphs.10R06FM"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709–717.","DOI":"10.1056\/NEJM199909023411001"},{"key":"6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030207"},{"key":"7","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(87)91030-7"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Hu X, Li S, McMahon EG, Lala DS, Rudolph AE. Molecular mechanisms of mineralocorticoid receptor antagonism by eplerenone. Mini Rev Med Chem. 2005;5:709–718.","DOI":"10.2174\/1389557054553811"},{"issue":"2","key":"9","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/S0022-3565(25)22580-0","volume":"240","year":"1987","ISSN":"https:\/\/id.crossref.org\/issn\/0022-3565","issn-type":"print"},{"key":"10","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.31.11.1448"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Cook CS, Zhang L, Ames GB, Fischer J, Zhang J, Levin S. Single- and repeated-dose pharmacokinetics of eplerenone, a selective aldosterone receptor blocker, in rats. Xenobiotica. 2003;33:305–321.","DOI":"10.1080\/0049825021000049277"},{"key":"12","doi-asserted-by":"publisher","DOI":"10.1016\/0960-0760(91)90104-D"},{"key":"13","doi-asserted-by":"publisher","DOI":"10.1016\/0022-4731(80)90237-X"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Kagawa CM. Blocking the renal electrolyte effects of mineralocorticoids with an orally active steroidal spirolactone. Endocrinology. 1960;67:125–132.","DOI":"10.1210\/endo-67-1-125"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Kagawa CM, Jacobs RS Jr. Mineralocorticoid effects of 9 alpha-fluorodeoxycorticosterone in adrenalectomized rats. Proc Soc Exp Biol Med. 1960;104:60–62.","DOI":"10.3181\/00379727-104-25726"},{"issue":"5","key":"16","doi-asserted-by":"crossref","first-page":"403","DOI":"10.2131\/jts.25.5_403","volume":"25","author":"SUNAMI O","year":"2000","ISSN":"https:\/\/id.crossref.org\/issn\/0388-1350","issn-type":"print"},{"key":"17","doi-asserted-by":"publisher","DOI":"10.1093\/toxsci\/53.2.289"},{"key":"18","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M504144200"},{"key":"19","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9673(97)01167-9"},{"key":"20","doi-asserted-by":"publisher","DOI":"10.1248\/bpb.28.1126"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21 Heikinheimo O, Gordon K, Williams RF, Hodgen GD. Inhibition of ovulation by progestin analogs (agonists vs antagonists): preliminary evidence for different sites and mechanisms of actions. Contraception. 1996;53:55–64.","DOI":"10.1016\/0010-7824(95)00255-3"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22 Tamura T, Yokoi R, Okuhara Y, Harada C, Terashima Y, Hayashi M, et al. Collaborative work on evaluation of ovarian toxicity. 2) Two- or four-week repeated dose studies and fertility study of mifepristone in female rats. J Toxicol Sci. 2009;34 Suppl 1:SP31–SP42.","DOI":"10.2131\/jts.34.S31"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23 Muhlemann MF, Carter GD, Cream JJ, Wise P. Oral spironolactone: an effective treatment for acne vulgaris in women. Br J Dermatol. 1986;115:227–232.","DOI":"10.1111\/j.1365-2133.1986.tb05722.x"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24 Moghetti P, Tosi F, Tosti A, Negri C, Misciali C, Perrone F, et al. Comparison of spironolactone, flutamide, and finasteride efficacy in the treatment of hirsutism: a randomized, double blind, placebo-controlled trial. J Clin Endocrinol Metab. 2000;85:89–94.","DOI":"10.1210\/jc.85.1.89"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25 Spritzer PM, Lisboa KO, Mattiello S, Lhullier F. Spironolactone as a single agent for long-term therapy of hirsute patients. Clin Endocrinol (Oxf). 2000;52:587–594.","DOI":"10.1046\/j.1365-2265.2000.00982.x"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26 Kelestimur F, Everest H, Unluhizarci K, Bayram F, Sahin Y. A comparison between spironolactone and spironolactone plus finasteride in the treatment of hirsutism. Eur J Endocrinol. 2004;150:351–354.","DOI":"10.1530\/eje.0.1500351"},{"key":"27","doi-asserted-by":"publisher","DOI":"10.1210\/en.138.8.3410"},{"key":"28","doi-asserted-by":"publisher","DOI":"10.1210\/en.2004-1130"},{"key":"29","doi-asserted-by":"publisher","DOI":"10.1097\/01.hjh.0000194122.27475.6c"}],"container-title":["Journal of Pharmacological Sciences"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,3,2]],"date-time":"2025-03-02T18:16:49Z","timestamp":1740939409000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jstage.jst.go.jp\/article\/jphs\/115\/3\/115_10285FP\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1254\/jphs.10285fp","relation":{},"ISSN":["1347-8613","1347-8648"],"issn-type":[{"value":"1347-8613","type":"print"},{"value":"1347-8648","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011]]}}}